The biotech market share report

Biotech industry market share graph featuring Amgen, Roche, Genentech, Johnson and Johnson, Novo Norisk, Eli Lilly, Sanofi-Aventis, Abbott, Merck KGaA, Schering-Plough and Wyeth

Who exactly are the biotech industry's biggest players? Everyone knows that Amgen and Genentech are dominant in the field, but a host of other companies also compete for a slice of the global biotech market. Sales of biologics amounted to $75 billion in 2007--just over 10 percent of the estimated $712 billion spent on prescription drugs last year. The combined marketshare of the top ten companies made up the bulk of those sales, coming to $61.4 billion.

There are certainly a number of drug developers, large and small, that hope to elbow their way on to this list. Biologic drugs are (for the time being, at least) insulated from generic competition, and many drug developers say they're putting more focus on biologics in the coming years. Sales of biotech drug grew 12.5 percent in 2007--twice as fast as the pharmaceutical market. In the face of generic competition and other market pressures, companies are looking for strategies to ensure their futures. Biologics offer an opportunity for growth that can't be ignored.

Check out out the top 10 biotech companies by sales--and a look at what's next in their pipelines

1. Amgen
2. Roche/Genentech
3. Johnson & Johnson
4. Novo Nordisk
5. Eli Lilly
6. Sanofi-Aventis
7. Abbott
8. Merck KGaA
9. Schering-Plough
10. Wyeth

Data courtesy of IMS Health


Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.